Aripiprazole Tablet
Product Images NDC 70518-4745

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-4745). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Aripiprazole 15mg 70518 4745 00)

Aripiprazole Tablet 15 mg, oral dosage form, packaged in a box of 50 tablets. The label includes the NDC number 70518-4745-00 and notes it is repackaged by RemedyRepack Inc., Indiana, PA. The tablet is described as round and white. Storage instructions and usual dosage information are also present.*

FDA Label Image

Remedy_label (Remedy Label)

Aripiprazole Tablet 15 mg oral tablet packaging label showing quantity of 1 tablet. The label includes the NDC number 70518-4745-01, manufacturer details indicating repackaging by RemedyRepack Inc. in Indiana, PA, and storage instructions. The tablet is described as round and white.*

FDA Label Image

Figure (Aripiprazole Fig1)

A scatter plot titled 'Effect of Other Drugs on Aripiprazole' showing the fold change and 90% confidence intervals of Aripiprazole's pharmacokinetic parameters (AUC and Cmax) influenced by various interacting drugs such as CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blockers famotidine, and other drugs including valproate, lithium, and lorazepam. The x-axis indicates change relative to a reference without interacting drug.*

FDA Label Image

Figure (Aripiprazole Fig2)

A chart showing the effect of other drugs on Aripiprazole pharmacokinetics, specifically the fold change and 90% confidence interval of Dehydro-Aripiprazole for AUC and Cmax values. The graph compares CYP3A4 inhibitors and inducers, gastric acid blockers, and other drugs, illustrating their impact relative to a reference without interacting drugs.*

FDA Label Image

Figure (Aripiprazole Fig3)

A forest plot graph showing the effect of Aripiprazole on the pharmacokinetics of various drugs, including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The x-axis represents the change relative to reference (without interacting drug), while the y-axis lists drugs and measures like AUC and Cmax.*

FDA Label Image

Figure (Aripiprazole Fig4)

A plot titled 'Aripiprazole Fold Change and 90% CI' showing pharmacokinetic parameters (AUC and Cmax) comparing different special populations such as CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The chart uses horizontal lines and squares to illustrate fold changes and confidence intervals relative to a reference value.*

FDA Label Image

Figure (Aripiprazole Fig5)

A chart showing the fold change and 90% confidence interval of Dehydro-Aripiprazole pharmacokinetic parameters (AUC and Cmax) relative to reference, comparing variables such as CYP2D6 metabolizer status, gender, age groups, and degrees of hepatic and renal impairment.*

FDA Label Image

Figure 6 (Aripiprazole Fig6)

A Kaplan-Meier survival curve chart comparing the proportion with relapse over days from randomization for Aripiprazole versus placebo. The x-axis represents days from randomization (0 to 182), and the y-axis shows the proportion with relapse (0 to 1.0). Below the chart, the number of subjects at risk for both groups is listed at various time points.*

FDA Label Image

Figure 7 (Aripiprazole Fig7)

A Kaplan-Meier curve chart displaying the proportion of subjects with relapse over time (days from randomization) comparing Aripiprazole and placebo groups. The y-axis represents the proportion with relapse, while the x-axis shows days from randomization up to 182 days. A table below the graph lists the number of subjects at risk at various time points for each group.*

FDA Label Image

Figure 8 (Aripiprazole Fig8)

A Kaplan-Meier survival curve chart showing the proportion of subjects with relapse over 364 days from randomization, comparing Aripiprazole and placebo groups. The chart includes a risk table beneath the x-axis indicating the number of subjects at risk at various time points during the study.*

FDA Label Image

Figure 9 (Aripiprazole Fig9)

A line graph showing the least-squares mean change in YGTSS total TIC score from baseline over 8 weeks of treatment. It compares three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo. The Y-axis represents the change in score, ranging from 0 to -20, and the X-axis represents weeks of treatment from 0 to 8. Both Aripiprazole groups show a greater reduction in tic scores compared to placebo over time.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Str)

Chemical structure of Aripiprazole, depicting its molecular arrangement including two chlorine atoms, a piperazine ring, and a quinolinone moiety connected by an oxygen-containing linker.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.